A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. - Tolcher AW; Bendell JC; Papadopoulos KP; Burris HA 3rd; Patnaik A; Jones SF; Rasco D; Cox DS; Durante M; Bellew KM; Park J; Le NT; et al. (Annals of oncology : official journal of the European Society for Medical Oncology, 2015)